Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Journal of Hand Surgery (European Volume)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by KIMANI, B. M.
Right arrow Articles by NUTTALL, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by KIMANI, B. M.
Right arrow Articles by NUTTALL, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Survivorship of the Neuflex Silicone Implant in MCP Joint Replacement

B. MWAURA KIMANI
I. A. TRAIL
A. HEARNDEN
R. DELANEY
D. NUTTALL

From the Wrightington Hospital, Wigan, UK

Correspondence: Mr I.A. Trail, MD, FRCS, Consultant Orthopaedic Surgeon, Wrightington Hospital, Hall Lane, Appley Bridge, Wigan WN6 9EP, UK. Tel.: +1257 256248. E-mail:upperlimb{at}wrightington.org.uk.

The Neuflex silicone metacarpophalangeal (MCP) joint replacement has previously been shown to provide improved movement, particularly flexion, when compared with the Swanson implant. In this study, we reviewed the outcome of 237 Neuflex implants in 66 patients with a follow-up of up to 7 years. Kaplan–Meier analysis using revision as the end stage revealed survival at 7 years to be 88%. If however an implant fracture, as seen radiographically, is taken as the end point, the survivorship drops to 68% at 7 years. These figures are comparable with a similar analysis for the Swanson implant. We conclude that the improved range of motion of the Neuflex implant demonstrated previously does not result in either a higher or a lower revision or implant fracture rate when compared with the Swanson implant.

Key Words: metacarpophalangeal (MCP) joint • Neuflex • fracture and revision surgery • survival analysis • terminal end points

Journal of Hand Surgery (European Volume), Vol. 34, No. 1, 25-28 (2009)
DOI: 10.1177/1753193408094437
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?